Chronic Pain Management Market Analysis

Nerve Blocks Market to Reach USD 9.4 Billion by 2033 at 6.4% CAGR

Chronic pain indications, including occipital nerve blocks for refractory migraine, stellate ganglion blocks, and sympathetic blocks, represent a growing outpatient clinic-based segment. A 2025-initiated study (nct:NCT07395908) is evaluating how greater occipital nerve pulse radiofrequency affects serum CGRP and PACAP-38 levels in chronic migraine, bridging the nerve block and neuromodulation spaces. Medtronic's FY2025 revenue of USD 33.54 billion (edgar:MDT-10K-2025) reflects its dominant position across both implantable neuromodulation and interventional pain, making it a key cross-competitive threat in the procedural pain space.